Nov 20, 2025 09:11AM Benchmark Reiterates Buy Rating on Clene, Inc. (CLNN)

Nov 14, 2025 07:06AM Clene (CLNN) Misses Q3 EPS by 85c

Sep 26, 2025 08:50AM Benchmark Reiterates Buy Rating on Clene, Inc. (CLNN)

Sep 10, 2025 08:52AM Clene, Inc. (CLNN) PT Lowered to $31 at Benchmark

Sep 5, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Clene, Inc. (CLNN)

Aug 18, 2025 06:41AM Clene, Inc. (CLNN) PT Lowered to $48 at Canaccord Genuity

Aug 14, 2025 04:40PM Clene (CLNN) Misses Q2 EPS by 78c

Jul 1, 2025 09:29AM Clene’s (CLNN) New Drug On Accelerated Approval Pathway: Benchmark

Jul 1, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Clene, Inc. (CLNN)

Jun 30, 2025 08:05AM Clene (CLNN) Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Jun 9, 2025 09:00AM Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

May 8, 2025 04:55PM Clene (CLNN) Misses Q1 EPS by 9c

May 7, 2025 08:00AM Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 8, 2025 08:07AM Clene (CLNN) Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session

Mar 25, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Clene, Inc. (CLNN)

Mar 24, 2025 04:52PM Clene (CLNN) Files $160M Mixed Shelf

Mar 13, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Clene, Inc. (CLNN)

Mar 12, 2025 08:02AM Clene (CLNN) Demonstrates Strengthened ALS Survival Benefit with CNM-Au8 Treatment

Feb 26, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Clene, Inc. (CLNN)

Feb 25, 2025 08:03AM Clene (CLNN) and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction

Jan 30, 2025 05:35PM Clene Inc. secures additional NIH grant funds for ALS therapy

Jan 24, 2025 04:15PM Clene (CLNN) Files for 1.15M Share Offering by Selling Stockholders

Nov 22, 2024 06:55AM Clene, Inc. (CLNN) PT Lowered to $84 at Benchmark

Nov 14, 2024 07:11AM Clene, Inc. (CLNN) PT Lowered to $83 at Canaccord Genuity

Nov 13, 2024 04:42PM Clene (CLNN) Misses Q3 EPS by 122c

Oct 10, 2024 06:18AM Canaccord Genuity Reiterates Buy Rating on Clene, Inc. (CLNN)

Oct 4, 2024 06:46AM Clene, Inc. (CLNN) PT Lowered to $86 at Canaccord Genuity

Sep 30, 2024 08:30AM Clene (CLNN) Announces $7.3M Offering

Sep 17, 2024 06:57AM H.C. Wainwright Reiterates Buy Rating on Clene, Inc. (CLNN)

Sep 16, 2024 08:32AM Clene (CLNN) Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Sep 10, 2024 07:04AM EF Hutton Starts Clene, Inc. (CLNN) at Buy

Aug 7, 2024 06:48AM Clene, Inc. (CLNN) PT Raised to $31 at H.C. Wainwright

Aug 6, 2024 08:02AM Clene (CLNN) Announces New CNM-Au8 Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS

Jul 9, 2024 08:01AM Clene (CLNN) Announces 1:20 Reverse Share Split

Jun 24, 2024 06:37AM H.C. Wainwright Reiterates Buy Rating on Clene, Inc. (CLNN)

Jun 21, 2024 07:10AM Clene (CLNN) Reports Prelim Data for CNM-Au8